RAAS Inhibitor Drugs in Dialysis Patients

Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes

Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether the upstream of aliskirne, a direct renin inhibitor improves mortality and cardiovascular outcomes in these high-risk population.

Inclusion Criteria:

• chronic kidney disease stage 5
• undergoing maintenance haemodialysis for a minimum of 3 months
• existing arterial hypertension or
• history of arterial hypertension or
• resting blood pressure ≥140/90 mmHg or
• antihypertensive medication
• man and female
• 18 years and older.

Exclusion Criteria:

• recent myocardial infarction (less than 3 months)
• atrial fibrillation/atrial flutter
• hypotension with systolic blood pressure of <90 mmHg
• high-grade aortic stenosis
• left ventricular ejection fration <50%
• known allergy to aliskiren
• severe disorders of liver function